PVR and neoplasm: Moreover, we established a tumor-bearing model model by subcutaneously injecting 4T1-CD155mock or 4T1-CD155KD cells to verify the antitumor efects of targeting TIGIT/CD155 signalling in vivo (Fig. 7F).